Evolving options for the treatment of metastatic breast cancer: Progression-free survival as an endpoint

Por Hurvitz, Sara A.
Publicado em 2011

The potential for trastuzumab emtansine in human epidermal growth factor receptor 2 positive metastatic breast cancer: latest evidence and ongoing studies

Por Hurvitz, Sara A., Kakkar, Reva
Publicado em 2012

Role of lapatinib alone or in combination in the treatment of HER2-positive breast cancer

Por Hurvitz, Sara A, Kakkar, Reva
Publicado em 2012

Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer

Por Peddi, Parvin F, Hurvitz, Sara A
Publicado em 2013

PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer

Por Peddi, Parvin F., Hurvitz, Sara A.
Publicado em 2014

Ado-trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: latest evidence and clinical potential

Por Peddi, Parvin F., Hurvitz, Sara A.
Publicado em 2014

Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine

Por Sadeghi, Saeed, Olevsky, Olga, Hurvitz, Sara A
Publicado em 2014

Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates

Por Wong, Deborah J.L., Hurvitz, Sara A.
Publicado no Ann Transl Med (2014)

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer

Por Hurvitz, Sara A., Lalla, Deepa, Crosby, Ross D., Mathias, Susan D.
Publicado em 2013

SERUM THYROTROPIN CONCENTRATIONS ARE NOT PREDICTIVE OF AGGRESSIVE BREAST CANCER BIOLOGY IN EUTHYROID INDIVIDUALS

Por Villa, Natalie M., Li, Ning, Yeh, Michael W., Hurvitz, Sara A., Dawson, Nicole A., Leung, Angela M.
Publicado no Endocr Pract (2015)

Relationship between HER2 expression and efficacy with first-line trastuzumab emtansine compared with trastuzumab plus docetaxel in TDM4450g: a randomized phase II study of patient...

Por Perez, Edith A, Hurvitz, Sara A, Amler, Lukas C, Mundt, Kirsten E, Ng, Vivian, Guardino, Ellie, Gianni, Luca
Publicado no Breast Cancer Res (2014)

Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

Por Hansen, Ryan N, Ramsey, Scott D, Lalla, Deepa, Masaquel, Anthony, Kamath, Tripthi, Brammer, Melissa, Hurvitz, Sara A, Sullivan, Sean D
Publicado em 2014

Cardiac safety results from a phase II, open-label, multicenter, pilot study of two docetaxel-based regimens plus bevacizumab for the adjuvant treatment of subjects with node-posit...

Por Hurvitz, Sara A, Bosserman, Linda D, Chan, David, Hagenstad, Christopher T, Kass, Frederick C, Smith, Frederick P, Rodriguez, Gladys I, Childs, Barrett H, Slamon, Dennis J
Publicado em 2014

HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve,...

Por Miller, Kathy, Cortes, Javier, Hurvitz, Sara A., Krop, Ian E., Tripathy, Debu, Verma, Sunil, Riahi, Kaveh, Reynolds, Joseph G., Wickham, Thomas J., Molnar, Istvan, Yardley, Denise A.
Publicado no BMC Cancer (2016)

A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity

Por Huang, Yao, Burns, David J, Rich, Benjamin E, MacNeil, Ian A, Dandapat, Abhijit, Soltani, Sajjad M., Myhre, Samantha, Sullivan, Brian F, Furcht, Leo T, Lange, Carol A, Hurvitz, Sara A, Laing, Lance G
Publicado no Oncotarget (2016)

Phase I Study of Ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with Relapsed and Refractory B-cell non-Hodgkin Lymphoma

Por Ansell, Stephen M., Hurvitz, Sara A., Koenig, Patricia A., LaPlant, Betsy R., Kabat, Brian F., Fernando, Donna, Habermann, Thomas M., Inwards, David J., Verma, Meena, Yamada, Reiko, Erlichman, Charles, Lowy, Israel, Timmerman, John M.
Publicado em 2009

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxa...

Por Hurvitz, Sara A., Dalenc, Florence, Campone, Mario, O’Regan, Ruth M., Tjan-Heijnen, Vivianne C., Gligorov, Joseph, Llombart, Antonio, Jhangiani, Haresh, Mirshahidi, Hamid R., Tan-Chiu, Elizabeth, Miao, Sara, El-Hashimy, Mona, Lincy, Jeremie, Taran, Tetiana, Soria, Jean-Charles, Sahmoud, Tarek, André, Fabrice
Publicado em 2013

Estrogen Receptor (ER)α-regulated Lipocalin 2 Expression in Adipose Tissue Links Obesity with Breast Cancer Progression

Por Drew, Brian G., Hamidi, Habib, Zhou, Zhenqi, Villanueva, Claudio J., Krum, Susan A., Calkin, Anna C., Parks, Brian W., Ribas, Vicent, Kalajian, Nareg Y., Phun, Jennifer, Daraei, Pedram, Christofk, Heather R., Hewitt, Sylvia C., Korach, Kenneth S., Tontonoz, Peter, Lusis, Aldons J., Slamon, Dennis J., Hurvitz, Sara A., Hevener, Andrea L.
Publicado no J Biol Chem (2015)

Analysis of Fcγ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients

Por Hurvitz, Sara A., Betting, David J., Stern, Howard M., Quinaux, Emmanuel, Stinson, Jeremy, Seshagiri, Somasekar, Zhao, Ying, Buyse, Marc, Mackey, John, Driga, Adrian, Damaraju, Sambasivarao, Sliwkowski, Mark X., Robert, Nicholas J., Valero, Vicente, Crown, John, Falkson, Carla, Brufsky, Adam, Pienkowski, Tadeusz, Eiermann, Wolfgang, Martin, Miguel, Bee, Valerie, Marathe, Omkar, Slamon, Dennis J., Timmerman, John M.
Publicado em 2012

MCT1 modulates cancer cell pyruvate export and growth of tumors that co-express MCT1 and MCT4

Por Hong, Candice Sun, Graham, Nicholas A., Gu, Wen, Camacho, Carolina Espindola, Mah, Vei, Maresh, Erin L., Alavi, Mohammed, Bagryanova, Lora, Krotee, Pascal A. L., Gardner, Brian K., Behbahan, Iman Saramipoor, Horvath, Steve, Chia, David, Mellinghoff, Ingo K., Hurvitz, Sara A., Dubinett, Steven M., Critchlow, Susan E., Kurdistani, Siavash K., Goodglick, Lee, Braas, Daniel, Graeber, Thomas G., Christofk, Heather R.
Publicado no Cell Rep (2016)